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Abstract
To generalize inferences from a randomized trial to the target population of all trial-
eligible individuals, investigators can use nested trial designs, where the randomized
individuals are nested within a cohort of trial-eligible individuals, including those who
are not offered or refuse randomization. In these designs, data on baseline covariates
are collected from the entire cohort, and treatment and outcome data need only be
collected from randomized individuals. In this paper, we describe nested trial designs
that improve research economy by collecting additional baseline covariate data after
sub-sampling non-randomized individuals (i.e., a two-stage design), using sampling
probabilities that may depend on the initial set of baseline covariates available from
all individuals in the cohort. We propose an estimator for the potential outcome mean
in the target population of all trial-eligible individuals and show that our estimator is
doubly robust, in the sense that it is consistent when either the model for the condi-
tional outcome mean among randomized individuals or the model for the probability
of trial participation is correctly specified. We assess the impact of sub-sampling on
the asymptotic variance of our estimator and examine the estimator’s finite-sample
performance in a simulation study. We illustrate the methods using data from the
Coronary Artery Surgery Study (CASS).
1 Background
Among individuals invited to participate in a randomized trial, those who agree to be ran-
domized often differ from those who decline in terms of variables that are modifiers of the
treatment effect. When that is the case, potential (counterfactual) outcome means and av-
erage treatment effects estimated in the trial do not directly apply to the target population
of all trial-eligible individuals. To address this problem, investigators can use a nested trial
design [1], where the randomized individuals are nested within a cohort of trial-eligible indi-
viduals, including those who are not offered or refuse randomization. In this design, baseline
covariate data are collected from all individuals in the cohort, but treatment and outcome
data need only be collected from randomized individuals. This is the basic study design
approach in comprehensive cohort studies [2, 3] and pragmatic randomized trials conducted
within large health-care systems [4].
When randomized and non-randomized individuals in nested trial designs are exchange-
able conditional on baseline covariates [5–9], we recently proposed efficient and robust esti-
mators for the potential (counterfactual) outcome means and the average treatment effect [1]
in the target population. The validity of the estimators depends on the conditional exchange-
ability of randomized and non-randomized individuals, thus, it is important to have informa-
tion on a rich enough set of baseline covariates, both from randomized and non-randomized
individuals, to render the condition plausible.
In many applications, the baseline covariates that can be easily collected from non-
randomized individuals are only a subset of the covariates collected from randomized individ-
uals. The common baseline covariates collected from both randomized and non-randomized
individuals may be insufficient for exchangeability and valid inference requires the collec-
tion of additional covariate information from the non-randomized individuals. When data
collection is expensive, research economy can be improved by using a two-stage design [10]
with sub-sampling of non-randomized individuals, that is, by collecting additional baseline
covariate information only among a subset of the non-randomized individuals. The subset
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of non-randomized individuals targeted for additional data collection may be selected using
sampling probabilities that depend on the initial set of baseline covariates.
In this paper we examine methods for generalizing causal inferences in nested trial designs
with sub-sampling of non-randomized individuals (i.e., two-stage designs), when the sampling
probabilities depend on the initial set of baseline auxiliary covariates. We propose an efficient
and robust estimator for the potential outcome means in the target population of all trial-
eligible individuals and show that our estimator is doubly robust, in the sense that it is
consistent when either the model for the conditional outcome mean among randomized
individuals or the model for the probability of trial participation is correctly specified. We
assess the impact of sub-sampling on the asymptotic variance of the estimator and examine
its finite-sample performance in a simulation study. We illustrate the application of the
methods using data from the Coronary Artery Surgery Study (CASS) [11].
2 Study designs and identifiability conditions
2.1 Nested trial designs with sub-sampling
We begin by considering nested trial designs, where a randomized trial is nested in a cohort
of trial-eligible individuals [1]. Let A be the assigned treatment that takes values in A, the
set of treatments assessed in the randomized trial (we only consider discrete treatments);
Y the observable outcome; X the (possibly high dimensional) vector of baseline covariates;
and S an indicator for trial participation (S = 1 for randomized individuals; S = 0 for
non-randomized individuals).
When baseline covariate data are collected from all individuals in the cohort, but treat-
ment and outcome data are collected only from randomized individuals, the observed data
are 
(X,S = 1, A, Y ), for randomized individuals;
(X,S = 0), for non-randomized individuals.
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Now, suppose that the baseline covariates are partitioned as X = (X1, X2) and that the
component X1 is readily available, whereas X2 is expensive to collect. For example, suppose
that a randomized trial is nested within a health-care system and that trial-eligible individ-
uals in the health-care system can be identified using routinely collected data. Claims and
electronic health record data (X1) are available from both randomized and non-randomized
individuals at very low cost. In contrast, specialized laboratory/ imaging test results, or
interview data (X2), which are collected from randomized individuals, may be unavailable in
the routinely collected data, expensive to collect (e.g., requiring manual chart abstraction),
and necessary to ensure randomized and non-randomized individuals are exchangeable (see
below).
In settings like this, to avoid collecting the expensive covariates on all non-randomized
individuals, it is natural to consider a two-stage design where we sample non-randomized
individuals for additional data collection, with sampling probabilities that may depend on
X1. We refer to this design as a nested trial with sub-sampling of non-randomized individuals.
For example, [12] described a special case of this design where the sampling probability was
not allowed to depend on baseline covariates. Following [12] and related work on two-stage
designs (e.g., [13–16]), we assume assume Bernoulli-type (independent) sampling [17, 18] of
non-randomized individuals.
Let D = 1 be an indicator for whether X2 data are collected from an individual; D = 1
for randomized individuals and sampled non-randomized individuals; D = 0 for non-sampled
non-randomized individuals. Using this notation, the observed data from a nested trial with
sub-sampling of non-randomized individuals are

(S = 1, D = 1, X,A, Y ) , for randomized individuals;
(S = 0, D = 1, X) , for sampled non-randomized individuals;
(S = 0, D = 0, X1) , for non-sampled non-randomized individuals.
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Figure 1 provides a schematic of the data structure and highlights that the observed data,
after sub-sampling of non-randomized individuals, have a monotone missing data pattern.
2.2 Sampling properties
In the nested trial design with sub-sampling of non-randomized individuals, we collect data
on baseline covariates X = (X1, X2); treatments, A; and outcomes, Y , from all randomized
individuals, such that
Pr[D = 1|X,A, Y, S = 1] = 1.
Furthermore, X1 data are collected from all non-randomized individuals, but X2 data are col-
lected only from a subset. The sampling probability with which non-randomized individuals
are selected for additional data collection depends only on X1, that is,
Pr[D = 1|X,A, Y, S = 0] = Pr[D = 1|X1, S = 0].
Thus, the study design ensures that D ⊥ (X,A, Y )|X1, S, which is a missing at random
condition [19]. Furthermore, by design, the sampling probability should be positive,
Pr[D = 1|X1 = x1, S = 0] > 0,
for all x1 that have positive density among non-randomized individuals, fX1|S(x1|S = 0) > 0.
In the context of case-referrent studies, an approach similar to ours has been termed “biased
sampling” [13] or “randomized recruitment” [14].
For convenience, we define the following conditional sampling probability function:
c(X1, S) ≡ Pr[D = 1|X1, S] = I(S = 1) + I(S = 0)× Pr[D = 1|X1, S = 0].
A special case occurs when sub-sampling non-randomized individuals with probabilities that
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do not depend on baseline covariates, in which case the sampling function becomes
c(S) ≡ Pr[D = 1|S] = I(S = 1) + I(S = 0)× c,
where c is a known constant, 0 < c < 1.
2.3 Causal quantities
In order to define the causal contrasts of interest, let Y a denote the potential (counterfactual)
outcome [20,21] under intervention to set treatment to a ∈ A.
We are interested in the potential outcome means in the target population of all trial-
eligible individuals, E[Y a]. These potential outcome means are of inherent scientific interest
and can also be used to identify average causal effects. For example, for a, a′ ∈ A, the
average treatment effect is E[Y a − Y a′ ] = E[Y a]− E[Y a′ ].
2.4 Identifiability conditions
We assume that the following identifiability conditions hold for each a ∈ A [1]: (I) Consis-
tency of potential outcomes: interventions are well-defined, so that if Ai = a, then Y
a
i = Yi.
Implicit in this notation is that the offer to participate in the trial and trial participation
itself do not have an effect on the outcome except through treatment assignment. (II) Mean
exchangeability among trial participants: E[Y a|X,S = 1, A = a] = E[Y a|X,S = 1]. This
condition is expected to hold because of randomization (marginal or conditional on X). (III)
Positivity of treatment assignment in the trial: Pr[A = a|X = x, S = 1] > 0 for each x with
positive density in the trial, fX(x|S = 1) > 0. (IV) Mean generalizability (exchangeability
over S): E[Y a|X,S = 1] = E[Y a|X]. Because S is binary, this condition implies the mean
transportability condition E[Y a|X,S = 1] = E[Y a|X,S = 0]. (V) Positivity of trial partic-
ipation: Pr[S = 1|X = x] > 0, for each x with positive density in the target population,
fX(x) > 0.
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Here, we have used X generically to denote baseline covariates. It is possible however,
that strict subsets of X are adequate to satisfy the different exchangeability conditions. For
example, in a marginally randomized trial the mean exchangeability among trial participants
holds unconditionally. Furthermore, to focus on issues related to selective trial participation,
we will assume complete adherence to the assigned treatment and no loss-to-follow-up.
3 Identification
Under identifiability conditions (I) through (V), the potential outcome mean under treat-
ment a in the target population, E[Y a], can be expressed as a function of the full (observable)
data,
E[Y a] = E
[
E[Y |X,S = 1, A = a]]
=
∫
E[Y |X = x, S = 1, A = a]dFX(x),
(1)
where FX(x) is the cumulative distribution function of X in the target population.
Because X = (X1, X2) is observed solely when D = 1, that is, among randomized
individuals and sampled non-randomized individuals, whereas only X1 is observed when
D = 0, the above result cannot be directly applied to the observed data in nested trial
designs with sub-sampling. In this design, however, as we show in Appendix A,
E
[
E[Y |X,S = 1, A = a]] = E [I(D = 1)
c(X1, S)
E[Y |X,S = 1, A = a]
]
= E
[
E
[
E[Y |X,S = 1, A = a]|X1, S,D = 1
]]
.
(2)
The above re-expression, together with the result in (1), shows that E[Y a] is identifiable in
the nested trial design with sub-sampling of non-randomized individuals.
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4 Estimation and inference
4.1 Estimation
We wish to estimate the functional ψ(a) = E
[
E
[
E[Y |X,S = 1, A = a]|X1, S,D = 1
]]
under the semi-parametric model described by the identifiability conditions and sampling
properties in Section 3. Using the efficient influence function [22] of ψ(a) (see Appendix B
for details), we obtain the following one-step, in-sample estimator of ψ(a),
ψ̂(a) =
1
n
n∑
i=1
{
b̂a(X1i, Si)+
I(Di = 1)
c(X1i, Si)
{
ĝa(Xi)−b̂a(X1i, Si)
}
+
I(Si = 1, Ai = a)
p̂(Xi)ea(Xi)
{
Yi−ĝa(Xi)
}}
,
(3)
where c(X1, S) = I(S = 1) + I(S = 0) × Pr[D = 1|X1, S = 0]; b̂a(X1, S) is an estimator
for E
[
E[Y |X,S = 1, A = a]|X1, S,D = 1
]
; p̂(X) is an estimator for Pr[S = 1|X]; ea(X) =
Pr[A = a|X,S = 1]; and ĝa(X) is an estimator for E[Y |X,S = 1, A = a]. Note that
Pr[D = 1|X1, S = 0] and Pr[A = a|X,S = 1] are known by design, but they may also be
estimated from the data. Estimating these known functions does not affect the large-sample
behavior of the estimator [23–26].
Estimating the probability of trial participation: The computation of ψ̂(a) requires the es-
timation of Pr[S = 1|X], the population probability of trial participation, which is not the
same as the probability of trial participation among sampled individuals, Pr[S = 1|X,D = 1].
Nevertheless, in the nested trial design with sub-sampling,
Pr[S = 1|X]
Pr[S = 0|X] =
Pr[S = 1|X,D = 1]
Pr[S = 0|X,D = 1] × c(X1, S = 0),
and, clearly, the right-hand-side of the above expression is identifiable.
A straightforward estimation approach is to posit a parametric model for the popula-
tion probability of trial participation, say, Pr[S = 1|X] = p(X; γ) with finite dimensional
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parameter γ. We can estimate γ by maximizing the pseudo-likelihood function
L (γ) =
n∏
i=1
[
p(Xi; γ)
]SiDi[1− p(Xi; γ)](1−Si)Di/c(X1i,Si).
Under reasonable technical conditions [27,28], the extremum estimator
γ̂ = arg max
γ∈Γ
n∑
i=1
{
SiDi log p(Xi; γ) +
(1− Si)Di
c(X1i, Si)
log
[
1− p(Xi; γ)
]}
,
where Γ is a compact parameter space, is a consistent estimator of γ, provided the population
model is correctly specified. Thus, for example, using weighted regression of S on X among
individuals with D = 1 (i.e., randomized and sampled non-randomized individuals), with
weights equal to 1/c(X1, S), we can obtain a consistent estimator of Pr[S = 1|X], provided
the parametric model p(X; γ) is correctly specified [28–30].
Double robustness: Suppose that b̂a(X1, S), ĝa(X), and p̂(X), have well-defined limiting
values b∗a(X1, S), g
∗
a(X), and p
∗(X), respectively. As we show in Appendix B, ψ̂(a) is doubly
robust in the following sense: ψ̂(a) converges in probability to ψ(a), that is, ψ̂(a)
p−→ ψ(a),
when either ĝa(X)
p−→ g∗a(X) = E[Y |X,S = 1, A = a] or p̂(X) p−→ p∗(X) = Pr[S = 1|X],
but not necessarily both, and regardless of whether b∗a(X1, S) is equal to E
[
E[Y |X,S =
1, A = a]
∣∣X1, S,D = 1].
Last, we note that when there is no sub-sampling, that is when baseline covariate data on
X are collected from all non-randomized individuals, c(X1, S) = 1 and D = 1 in the entire
sample, and the estimator becomes
ψ̂nosub(a) =
1
n
n∑
i=1
{
ĝa(Xi) +
I(Si = 1, Ai = a)
p̂(Xi)ea(Xi)
{
Yi − ĝa(Xi)
}}
. (4)
As we have shown before [1], this is the efficient estimator under the nested trial design
without sub-sampling non-randomized individuals in the cohort.
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4.2 Inference
In Appendix C we derive the asymptotic distribution of ψ̂(a) and thoroughly consider the
impact of model misspecification. Here, we outline some key results.
When ga(X) and p(X) are consistently estimated using correctly specified models (and
at sufficiently fast rate), ba(X1, S) is estimated at
√
n-rate (even with a misspecified model),
and regardless of whether c(X1, S) or ea(X) are estimated using correctly specified models
(and at sufficiently fast rate) or are known, the estimator in (3) is locally efficient, in the
sense that it attains the variance bound under the semi-parametric model defined by the
identifiability conditions, the sampling properties, and the additional model restrictions.
In Appendix D we show that, under correct model specification, the estimator has asymp-
totic variance
AVar1 = E
[
va(X)
p(X)ea(X)
]
+ Var
[
ga(X)
]
+ E
[
1− c(X1, S)
c(X1, S)
{
ga(X)− ba(X1, S)
}2]
, (5)
where va(X) = Var[Y |X,S = 1, A = a] and all quantities are evaluated at the true law.
The above result implies that, when models are correctly specified, the asymptotic variance
of the efficient estimator for the nested trial design sub-sampling in (3) is greater than or
equal to the asymptotic variance of the efficient estimator for the nested trial design without
sub-sampling non-randomized individuals in (4); see Appendix D for details.
To construct Wald-style confidence intervals for ψ(a), when using parametric models, we
can easily obtain the sandwich estimator [31] of the sampling variance of the estimator in
(3) by solving the appropriate estimating equation, jointly with the estimating equations for
the parameters of the working models for ba(X1, S), ga(X), and p(X) [25]. Alternatively,
we can use the non-parametric bootstrap [32]. The results presented in Appendix C ensure
that the bootstrap-based standard error estimator is valid [33].
A less computationally demanding large-sample (1 − α)% confidence interval for ψ(a)
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can be obtained [34] as
ψ̂(a)± z1−α/2ŜE
[
ψ̂(a)
]
,
where z1−α/2 is the (1− α/2)th quantile of the standard normal distribution and ŜE
[
ψ̂(a)
]
is given by
ŜE
[
ψ̂(a)
]
=
1
n
√√√√ n∑
i=1
ÎC
2
i ,
and
ÎCi = b̂a(X1i, Si) +
I(Di = 1)
c(X1i, Si)
{
ĝa(Xi)− b̂a(X1i, Si)
}
+
I(Si = 1, Ai = a)
p̂(Xi)ea(Xi)
{
Yi − ĝa(Xi)
}
.
5 Simulation study
5.1 Methods
Building on our earlier work [1], we conducted a simulation study to examine the finite-
sample performance of the estimator in (3) when sub-sampling non-randomized individuals,
and compare it against the estimator in (4), without sub-sampling. We simulated scenarios
using trials with an average sample size of 1000 individuals nested in cohorts of 2000, 5000, or
10,000 individuals and scenarios using trials with an average sample size of 2000 individuals
nested in cohorts of 5000, 10,000, or 20,000 individuals. Appendix E provides details about
the scenarios we considered.
Nested trial data generation: We generated data for three baseline covariates, Zj, j = 1, 2, 3.
Thus, in the notation of the previous section, (Z1, Z2, Z3) = X. For Z1, we considered both
continuous and binary distributions; for the continuous case, Z1 ∼ N (0, 1); for the binary
case, Z1 ∼ Bernoulli(0.5). For j = 2, 3, we used Zj ∼ N (0, 1), i = 1, ..., n. We generated
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“selection” into the trial using a logistic linear model for the trial participation indicator,
S ∼ Bernoulli(Pr[S = 1|Z]) with Pr[S = 1|Z] = exp(γZ
T )
1 + exp(γZT )
,
Z = (1, Z1, . . . , Z3), γ = (γ0, 1, 1, 1), and intercept γ0 chosen for each n such that it resulted
in randomized trials with the desired average sample size (see Appendix E). We determined
the γ0 for each scenario using the numerical methods described in [35]. We generated an
indicator of unconditionally randomized treatment assignment, A, among randomized in-
dividuals using a Bernoulli distribution with parameter Pr[A = 1|S = 1] = 0.5. We then
generated continuous outcomes using linear potential outcome models with normally dis-
tributed errors: Y a = θaZT + a, for a ∈ {0, 1}, where θa = (θa0 , . . . , θa3), a ∈ {0, 1}. We
set θ0 = (1, 1, 1, 1) and θ1 = (0, 0, 0, 1) (i.e., effect modification by both Z1 and Z2). In
all simulations, a had a standard normal distribution for a = 0, 1. We generated observed
outcomes as Y = AY 1 + (1− A)Y 0.
Sub-sampling of non-randomized individuals: We assumed that Z1 was measured on all
cohort members, but Z2 and Z3 were only measured on randomized individuals and sampled
non-randomized individuals. In the notation of the previous section, Z1 = X1 and (Z2, Z3) =
X2. After generating the cohort data, we sub-sampled non-randomized observations (S = 0)
using a logistic linear model,
D
∣∣Z, S = 0 ∼ Bernoulli(Pr[D = 1|Z1, S = 0]) with Pr[D = 1|Z1, S = 0] = exp(ζ0 + Z1)
1 + exp(ζ0 + Z1)
,
with the intercept, ζ0, chosen for each cohort sample size, Z1 distribution (continuous or
binary), and marginal probability of trial participation, such that it resulted in marginal
sampling probabilities of non-randomized individuals, Pr[D = 1|S = 0], ranging from 0.1
to 0.9, in steps of 0.1 (see Appendix Tables E.1 and E.2 for details). As for selective trial
participation, we determined the ζ0 for each scenario using the numerical methods described
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in [35]. We also considered a case where the sampling probability did not depend on baseline
covariates, but instead a simple random sample of the non-randomized patients was taken.
For all randomized individuals, we set D = 1 in all simulations.
Comparisons and performance measures: In each simulated dataset, we applied estimator
(3) to the sub-sampled data and estimator (4) to non-sub-sampled data. For each estimator,
we estimated bias, variance, and mean squared error over 10,000 runs for each scenario.
In the simulations, the working models for ga(Z) = E[Y |Z, S = 1, A = a], ea(Z) =
Pr[A = a|Z, S = 1], and p(Z) = Pr[S = 1|Z] were correctly specified, in the sense that
the true model was included within the class of models under consideration. Specifically,
models for the probability of participation in the trial and models for the probability of
treatment included all main covariate effects; outcome models were fitted separately to each
treatment group (i.e., allowed for all possible treatment by covariate interactions over all
covariates). For ba(Z1, S) = E
[
E[Y |Z, S = 1, A = a]∣∣Z1, S,D = 1] we used the linear model
ba(Z1, S) = ξ0+ξ1Z1+ξ2S+ξ3Z1×S. We estimated c(Z1, S = 0) = Pr[D = 1|Z1, S = 0] using
a correctly specified logistic model with Z1 as the only covariate, fit among non-randomized
individuals; and we set c(Z1, S = 1) = Pr[D = 1|Z1, S = 1] = 1.
5.2 Results
Complete results from the simulation study are presented in Appendix Tables E.3 through
E.10. In all simulations, when all models were correctly specified, estimator (3), which
uses the sub-sampled data, was nearly unbiased, for marginal sampling probabilities of non-
randomized individuals ranging from 0.1 to 0.9, despite the presence of strong selection on
baseline covariates and strong effect modification. As expected based on prior work [1], the
estimator in (4), which uses the non-sub-sampled data, was also nearly unbiased.
Results for the sampling variance of the estimators for scenarios with an average trial
sample size of 1000 observations are graphed in Figure 2; results for scenarios with an average
trial sample size of 2000 observations are graphed in Appendix Figure E.1. For both trial
12
sample sizes and regardless of the cohort sample size, with increasing marginal sampling
probability of non-randomized individuals, the variance of the estimator in (3) approached
the variance of the estimator in (4) (the latter applied only to data without sub-sampling).
In this simulation, the sampling variances of the two estimators were quite similar once the
marginal sampling probability was greater than 0.3.
Results were similar when the sampling probabilities depended on Z1, a baseline covariate
that was both an effect modifier and a strong predictor of trial participation (both when Z1
was continuous and discrete), and when the sub-sampling did not depend on Z1 (i.e., in the
case of simple random sampling). Of note, in all simulation scenarios the sampling variance
was larger with increasing cohort size, because, holding the trial sample size and the selection
and sub-sampling mechanisms constant, the difference in the covariate distribution between
randomized and non-randomized observations increases as the cohort sample size increases
(i.e., as the marginal probability of trial participation decreases).
6 The Coronary Artery Surgery Study (CASS)
6.1 CASS design and data
CASS was a comprehensive cohort study that compared coronary artery bypass grafting
surgery plus medical therapy (henceforth, “surgery”) versus medical therapy alone for in-
dividuals with chronic coronary artery disease; details about the design of CASS are avail-
able elsewhere [11, 36]. In brief, individuals undergoing angiography in 11 institutions were
screened for eligibility and the 2099 trial-eligible individuals who met the study criteria were
either randomized to surgery or medical therapy (780 individuals), or included in an ob-
servational study (1319 individuals). We excluded 6 individuals for consistency with prior
CASS analyses and in accordance with CASS data release notes; in total we used data from
2093 individuals (778 randomized; 1315 non-randomized). Baseline covariates were collected
from randomized and non-randomized individuals in an identical manner. No randomized
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individuals were lost to follow-up in the first 10 years of the study; we did not use informa-
tion on adherence among randomized individuals, in effect assuming that the non-adherence
would be similar among all eligible individuals.
In [1] we used these data to illustrate generalizability methods for nested trial designs
without sub-sampling. Here, we build on that work to illustrate the use of methods that are
appropriate when the full covariate data is only obtained from a subset of non-randomized
individuals. To do so, we emulated the sub-sampling design under a variety of scenarios.
We assumed that clinical covariates were measured on all cohort members (both random-
ized and non-randomized), but laboratory covariates were only measured on randomized
individuals and sampled non-randomized individuals. We sub-sampled the non-randomized
individuals using (1) covariate-dependent sampling of non-randomized individuals, where
sampling depended on past history of myocardial infarction, such that individuals without
a history of infarction had double the probability of being sampled compared to individuals
with such history, and marginal probability of sampling ranging from 0.1 to 0.7, in steps of
0.1 (sampling probabilities of 0.8 and 0.9 were not possible to implement while preserving
the aforementioned relationship between the sampling probabilities of individuals with and
without history of infarction because they corresponded to probabilities greater than 1 for
one of these subgroups); and (2) simple random sampling of non-randomized individuals
with probabilities that ranged from 0.1 to 0.9, in steps of 0.1.
6.2 Statistical analysis
Estimands and estimators: We estimated the 10-year mortality risk under surgery and med-
ical therapy, and the risk difference comparing the treatments for the target population of all
trial-eligible individuals. We applied the estimator in (3) to sub-sampled data and compared
it against the estimator in (4) applied to the original, non-sub-sampled, data.
Working models: We fit logistic regression models for the probability of participation in
the trial among sub-sampled individuals, the probability of treatment among randomized
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individuals, and the probability of the outcome (in each treatment arm), conditional on
clinical covariates (age, severity of angina, history of previous myocardial infarction) and
laboratory covariates (percent obstruction of the proximal left anterior descending artery,
left ventricular wall motion score, number of diseased vessels, and ejection fraction). We
chose these variables based on a previous analysis of the same data [3].
We considered three ways of obtaining the probability of sampling a non-randomized
individual for use in (3): (1) use the “design-based” (known) sampling probabilities; (2)
estimate the sampling probabilities, that is, use the empirical proportion in simple random
sampling scenarios, or estimate the probability using a logistic regression model with history
of infarction as the only covariates in covariate-dependent sampling scenarios; and (3) esti-
mate the sampling probabilities using a logistic regression model that inlcuded all clinical
covariates (even if not used to determine the sampling probabilities by design).
Missing baseline covariate data: Of the 2093 trial-eligible individuals, 1686 had complete
data on all baseline covariates (731 randomized, 368 in the surgery group and 363 in the
medical therapy group; 955 non-randomized). In [1] we undertook extensive missing data
analyses under a missing at random assumption, which produced results very similar to
those of the complete case analyses. For simplicity, here, we only report analyses restricted
to individuals with complete data.
Inference: For all analyses, we used bootstrap resampling (with 10,000 samples) to esti-
mate standard errors.
6.3 Results
We summarize comparisons as ratios of the estimated standard error of the estimator in
(3), for each sub-sampling scenario and for each method of obtaining the sub-sampling
probability, divided by the standard error of the estimator in (4) applied to the original
CASS data. In general, except when the marginal sampling probability was less than 0.2, the
standard errors were very similar, suggesting that sub-sampling non-randomized individuals
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in this example would not have adversely affected precision. Figure E.2 and Appendix Figure
3 summarize results from analyses under covariate-dependent and simple random sampling,
respectively.
7 Discussion
We provide identification and estimation results for nested trial designs with sub-sampling
of non-randomized individuals. These designs aim to support the generalization of causal in-
ferences from randomized trials to the target population of all trial-eligible individuals, while
improving research economy by limiting the collection of baseline covariates (in particular,
covariates that are expensive to collect) to a subset of non-randomized individuals.
Nested trial designs will be increasingly implemented in conjunction with pragmatic
randomized trials [37] because data from these trials can be linked with routinely collected
(“real-world”) data (e.g., insurance claims or electronic health records). This linkage creates
datasets that merge the trial data with routinely collected observational data, with a common
set of baseline covariates available both from randomized and non-randomized trial-eligible
individuals. In applications, the generalization of inferences from the randomized individuals
to the target population of all trial-eligible individuals will often require information on
covariates that are collected in the randomized trial but are not readily available in the
routinely collected observational data (e.g., specialized imaging or laboratory tests). When
additional data collection from non-randomized individuals is necessary, sub-sampling of
non-randomized individuals for additional data collection, combined with efficient statistical
estimation methods, can support inferences that are almost as precise as those possible by
collecting data from all non-randomized individuals, but at a fraction of the cost.
In our simulations and the CASS re-analysis, we found that the performance of our
sub-sampling estimator quickly approached that of the efficient estimator under no sub-
sampling as the marginal probability of sampling non-randomized individuals increased. We
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conjecture that this pattern should be expected in most cases because the main contribution
of the sampled non-randomized individuals is in the estimation of the conditional covariate
distribution, FX|S(x|S = 0); this conditional distribution enters the identification result in
(1), because FX(x) =
∑
s FX|S(x|S = s) Pr[S = s]. Provided the total cohort sample size is
fairly large and the sampling mechanism is reasonably chosen (e.g., sampling probabilities are
away from 0), FX|S(x|S = 0) is estimated well even at low marginal sampling probabilities.
Thus, in practical applications of nested trial designs with sub-sampling of non-randomized
individuals, it will often be wise to focus resources on better estimating E[Y |X,S = 1, A = a]
and FX|S(x|S = 1), by increasing the sample size of the randomized trial. Such focus will
also serve to strengthen the trial-specific inferences that are the usual reason for conducting
the trial in the first place [38].
In summary, we have described nested trial designs with sub-sampling of non-randomized
individuals for generalizing causal inferences from randomized trials to the target population
of all trial-eligible individuals. Our study of efficient and robust estimation methods for these
designs suggests that sub-sampling can improve research economy without severely affecting
precision.
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9 Figures
Figure 1: Schematic of the observed data structure for nested trial designs with sub-sampling
of non-randomized individuals. Gray shading indicates that the variable is not measured on
some of the individuals in the cohort.
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Figure 2: Simulation results for the sampling variance of estimators for ψ(a), a = 0, 1 and
ψ(1) − ψ(0), with average trial sample size of 1000 observations. Results in each panel are
shown for different data generating mechanisms (binary or continuous Z1) and sampling
mechanisms (dependent on Z1 or simple random sampling, SRS). In all panels, results are
shown for ψ̂(a) under marginal sampling probabilities ranging from 0.1 to 0.9, in steps of
0.1 (black markers); and for ψ̂nosub(a) under no sub-sampling (white markers). In each panel,
results are shown for cohort sample sizes of 2000 (circles), 5000 (triangles), and 10,000
(squares) individuals.
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Figure 3: CASS analysis results comparing the estimated standard errors of the estimator
in (3) for ψ(a), a = 0, 1 and ψ(1) − ψ(0), under covariate dependent sampling with sam-
pling probabilities of non-randomized individuals that depended on history of myocardial
infarction, against the estimator in (4); see main text for details. In all panels, standard
error ratios are shown for marginal sampling probabilities ranging from 0.1 to 0.7, in steps
of 0.1 (in this analysis marginal probabilities of 0.8 or 0.9 were infeasible under the chosen
covariate dependence relationship).
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Appendix A Identification
Proposition 1. Under the identifiability conditions I through V listed in the main text,
E[Y a] = E
[
E[Y |X,S = 1, A = a]].
Proof:
E[Y a] = E
[
E[Y a|X]]
= E
[
E[Y a|X,S = 1]]
= E
[
E[Y a|X,S = 1, A = a]]
= E
[
E[Y |X,S = 1, A = a]].
Proposition 2. In the nested trial design with sub-sampling of non-randomized individuals,
where c(X1, S) ≡ Pr[D = 1|X1, S], and, by design, Pr[D = 1|X,A, Y, S] = Pr[D = 1|X1, S],
E
[
E[Y |X,S = 1, A = a]] = E [I(D = 1)
c(X1, S)
E[Y |X,S = 1, A = a]
]
= E
[
E
[
E[Y |X,S = 1, A = a]|X1, S,D = 1
]]
.
Proof: For the first equality,
E
[
I(D = 1)
c(X1, S)
E[Y |X,S = 1, A = a]
]
= E
[
E
[
I(D = 1)
c(X1, S)
E[Y |X,S = 1, A = a]
∣∣∣X,A, Y, S]]
= E
[
E[Y |X,S = 1, A = a]
c(X1, S)
E[I(D = 1)|X,A, Y, S]
]
= E
[
E[Y |X,S = 1, A = a]],
where the last equality follows from the sampling properties of nested-trial design, using
Pr[D = 1|X,A, Y, S] = Pr[D = 1|X1, S] = c(X1, S).
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For the second equality,
E
[
E
[
E[Y |X,S = 1, A = a]|X1, S,D = 1
]]
= E
[
E
[
E[Y |X,S = 1, A = a]|X1, S
]]
= E
[
E[Y |X,S = 1, A = a]]
where the first equality follows from the fact that, by design, D⊥ (X,A, Y )|X1, S.
Remark. Our derivation for Proposition 2 only uses the sampling properties of the nested
trial design with sub-sampling of non-randomized individuals and does not use any of the
structural identifiability conditions. Thus, the result holds even when ψ(a) does not have any
causal interpretation.
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Appendix B Estimation and double robustness
B.1 Influence function
The influence function of ψ(a) is
Ψ10(a) = ba(X1, S) +
I(D = 1)
c(X1, S)
{
ga(X)− ba(X1, S)
}
+
I(S = 1, A = a)
p(X)ea(X)
{
Y − ga(X)
}
− ψ(a),
where
ba(X1, S) = E
[
E[Y |X,S = 1, A = a]|X1, S,D = 1
]
,
c(X1, S) = Pr[D = 1|X1, S],
ga(X) = E[Y |X,S = 1, A = a],
p(X) = Pr[S = 1|X], and
ea(X) = Pr[A = a|X,S = 1],
and all quantities are evaluated at the “true” law.
B.2 Connection with two-stage designs
Applying the theory for two-stage designs from [10], we obtain the following expression for
the influence function for nested trials with sub-sampling of non-randomized individuals:
Ψ˜10(a) =
I(D = 1)
c(X1, S)
Ψ1∗0 (a) +
{
1− I(D = 1)
c(X1, S)
}
E
[
Ψ1∗0 (a)
∣∣X1, S,D = 1], (B.1)
where Ψ1∗0 (a) is the influence function under the nested trial design without sub-sampling
(census) of non-randomized individuals [1],
Ψ1∗0 (a) =
I(S = 1, A = a)
p(X)ea(X)
{
Y − ga(X)
}
+ ga(X)− ψ(a), (B.2)
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and, as before, all quantities are evaluated at the “true” law. We will now show that the
above result is in agreement with our result in Section B.1.
Proposition 3. In the nested trial design with sub-sampling of non-randomized individuals,
Ψ10(a) = Ψ˜
1
0(a). (B.3)
Proof: We begin work on the right-hand-side of equation (B.3), plugging the no-sub-sampling
influence function from (B.2) into equation (B.1):
Ψ˜10(a) =
I(D = 1)
c(X1, S)
{
I(S = 1, A = a)
p(X)ea(X)
{
Y − ga(X)
}
+ ga(X)− ψ(a)
}
+
{
1− I(D = 1)
c(X1, S)
}
E
[
I(S = 1, A = a)
p(X)ea(X)
{
Y − ga(X)
}
+ ga(X)− ψ(a)
∣∣∣∣∣X1, S,D = 1
]
Noting that if S = 1, then c(X1, S) = 1 and D = 1, we obtain
Ψ˜10(a) =
I(S = 1, A = a)
p(X)ea(X)
{
Y − ga(X)
}
+
I(D = 1)
c(X1, S)
{
ga(X)− ψ(a)
}
+
{
1− I(D = 1)
c(X1, S)
}
E
[
I(S = 1, A = a)
p(X)ea(X)
{
Y − ga(X)
}
+ ga(X)− ψ(a)
∣∣∣∣∣X1, S,D = 1
]
.
Next, we note that,
E
[
I(S = 1, A = a)
p(X)ea(X)
{
Y − ga(X)
}
+ ga(X)− ψ(a)
∣∣∣∣∣X1, S,D = 1
]
= E
E[I(S = 1, A = a)
p(X)ea(X)
{
Y − ga(X)
}∣∣∣∣∣X,A, S,D = 1
]
X1, S,D = 1

+ E
[
ga(X)− ψ(a)
∣∣X1, S,D = 1]
= E
[
ga(X)− ψ(a)
∣∣X1, S,D = 1]
= ba(X1, S)− ψ(a).
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Using the above result, we see that
Ψ˜10(a) =
I(S = 1, A = a)
p(X)ea(X)
{
Y − ga(X)
}
+
I(D = 1)
c(X1, S)
{
ga(X)− ψ(a)
}
+
{
1− I(D = 1)
c(X1, S)
}{
ba(X1, S)− ψ(a)
}
= ba(X1, S) +
I(D = 1)
c(X1, S)
{
ga(X)− ba(X1, S)
}
+
I(S = 1, A = a)
p(X)ea(X)
{
Y − ga(X)
}
− ψ(a)
= Ψ10(a),
,
which completes the proof.
B.3 One-step in-sample estimator
The influence function in section B.1 suggests the following in-sample one-step estimator
ψ̂(a) =
1
n
n∑
i=1
{
b̂a(X1i, Si) +
I(D = 1)
c(X1i, Si)
{
ĝa(Xi)− b̂a(Si, X1i)
}
+
I(Si = 1, Ai = a)
p̂(Xi)ea(Xi)
{
Yi − ĝa(Xi)
}}
=
1
n
n∑
i=1

{
1− I(Di = 1)
c(X1i, Si)
}
b̂a(X1i, Si) +
I(Di = 1)
c(X1i, Si)
ĝa(Xi) +
I(Si = 1, Ai = a)
p̂(Xi)ea(Xi)
{
Yi − ĝa(Xi)
} ,
where c(X1, S) and ea(X) are known by design (or, alternatively, can be consistently esti-
mated).
B.4 Double robustness
We now consider the behavior of the estimator in Section B.3, using the “true” sampling
probability, c(X1, S) = Pr[D = 1|X1, S], and the “true” probability of treatment among
randomized individual, ea(X) = Pr[A = a|X,S = 1].
Suppose that b̂a(X1, S), ĝa(X), and p̂(X) have well-defined limiting values, which we
denote as b∗a(X1, S), g
∗
a(X), and p
∗(X), respectively.
Proposition 4. In the nested trial design with sub-sampling of non-randomized individuals,
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ψ̂(a) is doubly robust in the sense that, ψ̂(a)
p−→ ψ(a) = E [E[Y |X,S = 1, A = a]], when
either ĝa(X)
p−→ g∗a(X) = E[Y |X,S = 1, A = a] or p̂(X) p−→ p∗(X) = Pr[S = 1|X].
Proof: As n→∞, we have that
ψ̂(a)
p−→ E
{1− I(D = 1)
c(X1, S)
}
b∗a(X1, S) +
I(D = 1)
c(X1, S)
g∗a(X) +
I(S = 1, A = a)
p∗(X)ea(X)
{
Y − g∗a(X)
} .
(B.4)
First, we note that by design,
E
{1− I(D = 1)
c(X1, S)
}
b∗a(X1, S)
 = 0,
regardless of whether b∗a(X1, S) = E
[
E[Y |X,S = 1, A = a]∣∣X1, S,D = 1].
Next, we study the expectation of the remaining two terms in (B.4) by examining cases.
Case 1: g∗a(X) = E[Y |X,S = 1, A = a], but p∗(X) 6= Pr[S = 1|X]: We have that
E
[
I(D = 1)
c(X1, S)
g∗a(X) +
I(S = 1, A = a)
p∗(X)ea(X)
{
Y − g∗a(X)
}]
= E
[
I(D = 1)
c(X1, S)
E[Y |X,S = 1, A = a]
]
= E
E[Y |X,S = 1, A = a]
c(X1, S)
E[I(D = 1)|X,A, Y, S
]
= E
[
E[Y |X,S = 1, A = a]].
Thus, if g∗a(X) = E[Y |X,S = 1, A = a], then ψ̂(a) p−→ E
[
E[Y |X,S = 1, A = a]].
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Case 2: p∗(X) = Pr[S = 1|X], but g∗a(X) 6= E[Y |X,S = 1, A = a]: We have that
E
[
I(D = 1)
c(X1, S)
g∗a(X) +
I(S = 1, A = a)
p∗(X)e∗a(X)
{
Y − g∗a(X)
}]
= E
{I(D = 1)
c(X1, S)
− I(S = 1, A = a)
p∗(X)ea(X)
}
g∗a(X) +
I(S = 1, A = a)
p∗(X)ea(X)
Y

= E
[
I(S = 1, A = a)
Pr[S = 1|X] Pr[A = a|X,S = 1]Y
]
= E
[
E[Y |X,S = 1, A = a]].
Thus, if p∗(X) = Pr[S = 1|X], then ψ̂(a) p−→ E [E[Y |X,S = 1, A = a]].
Taken together, Cases 1 and 2 establish the double robustness of ψ(a).
Remark. Consistently estimating the sampling probability, c(X1, S), and the probability of
treatment among randomized individuals, ea(X), does not affect the double robustness of the
estimator in Section B.3. The reason is that these probabilities are under the control of the
investigators and it is always possible to select estimators ĉ(X1, S) and êa(X), that have
well-defined limiting values, c∗(X1, S) and e∗a(X), respectively, such that
ĉ(X1, S)
p−→ c∗(X1, S) = Pr[D = 1|X1, S]
and
êa(X)
p−→ e∗a(X) = Pr[A = a|X,S = 1].
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Appendix C Asymptotic distribution
Recall that
ψ̂(a) =
1
n
n∑
i=1
{
b̂a(X1i, Si) +
I(Di = 1)
c(X1i, Si)
{
ĝa(Xi)− b̂a(X1i, Si)
}
+
I(Si = 1, Ai = a)
p̂(Xi)ea(Xi)
{
Yi − ĝa(Xi)
}}
.
As before, b∗a(X1, S), g
∗
a(X), and p
∗(X) denote the asymptotic limits of the potentially mis-
specified models b̂a(X1, S), ĝa(X), and p̂(X), respectively. For any functions b
′
a(X1, S),
g′a(X), and p
′(X) define
H(b′a, g
′
a, p
′) = b′a(X1, S) +
I(D = 1)
c(X1, S)
{
g′a(X)− b′a(X1, S)
}
+
I(S = 1, A = a)
p′(X)ea(X)
{
Y − g′a(X)
}
.
Using standard empirical processes notation [39], denote
Pn(H(b′a, g′a, p′))
=
1
n
n∑
i=1
{
b′a(X1i, Si) +
I(Di = 1)
c(X1i, Si)
{
g′a(Xi)− b′a(X1i, Si)
}
+
I(Si = 1, Ai = a)
p′(Xi)ea(Xi)
{
Yi − g′a(Xi)
}}
and letGn(H(b′a, g′a, p′)) =
√
n(Pn(H(b′a, g′a, p′))−E[H(b′a, g′a, p′)]). Note that ψ̂(a) = Pn(H (̂ba, ĝa, p̂)).
The derivation of the asymptotic distribution relies on the following additional assump-
tions:
A.1 The sequence H (̂ba, ĝa, p̂) and the limit H(b
∗
a, g
∗
a, p
∗) fall in a Donsker class [39].
A.2 We have ||H (̂ba, ĝa, p̂)−H(b∗a, g∗a, p∗)||2 → 0.
A.3 We have E[H(b∗a, g
∗
a, p
∗)2] <∞.
If b̂a, ĝa, p̂, b
∗
a, g
∗
a, and p
∗ all fall in a Donsker class; p∗ is uniformly bounded away from zero;
and g∗a is uniformly bounded, then assumption A.1 follows from Corollary 9.31 in [40].
The following Proposition gives the asymptotic distribution of the estimator ψ̂(a).
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Proposition 5. Under the assumptions made, in the nested trial design with sub-sampling
of non-randomized individuals,
√
n(ψ̂(a)− ψ(a)) = Gn(H(b∗a, g∗a, p∗)) +R + oP (1),
where Gn(H(b∗a, g∗a, p∗)) is asymptotically normal and
R ≤ √nOP
(
||ĝa(X)− E[Y |X,S = 1, A = a]||2||P̂r[S = 1, A = a|X]− Pr[S = 1, A = a|X]||2
)
.
Proof: Decompose
√
n(ψ̂(a)− ψ(a)) as
√
n(ψ̂(a)− ψ(a)) =
(
Gn(H (̂ba, ĝa, p̂))−Gn(H(b∗a, g∗a, p∗))
)
+Gn(H(b∗a, g∗a, p∗))
+
√
n
(
E[H (̂ba, ĝa, p̂)])− ψ(a)
)
.
All convergence results presented here are in terms of n→∞. The proof relies on working
with each of the terms on the right-hand-side of the above equation separately.
For the first term in the decomposition of
√
n(ψ̂(a) − ψ(a)), by the Donsker property
[39,41] of H (̂ba, ĝa, p̂) and H(b
∗
a, g
∗
a, p
∗), we have
(
Gn(H (̂ba, ĝa, p̂))−Gn(H(b∗a, g∗a, p∗))
)
= oP (1).
The second term, Gn(H(b∗a, g∗a, p∗)), in the decomposition is asymptotically normal by the
central limit theorem. Hence, the asymptotic distribution of ψ̂(a) depends on the behavior
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of the third term,
√
n
(
E[H (̂ba, ĝa, p̂)]− ψ(a)
)
. We re-write the third term as
√
n
(
E[H (̂ba, ĝa, p̂)])− ψ(a)
)
=
√
n
(
E
[
b̂a(X1, S) +
I(D = 1)
c(X1, S)
{
ĝa(X)− b̂a(X1, S)
}
+
I(S = 1, A = a)
p̂(X)ea(X)
{
Y − ĝa(X)
}]
− ψ(a)
)
=
√
nE
[
b̂a(X1, S)
{
1− I(D = 1)
c(X1, S)
}]
︸ ︷︷ ︸
R1
+
√
nE
[
I(D = 1)
c(X1, S)
ĝa(X) +
I(S = 1, A = a)
p̂(X)ea(X)
{
Y − ĝa(X)
}
− ψ(a)
]
︸ ︷︷ ︸
R
.
First, we rewrite R1 as
R1 =
√
nE
[
b∗a(X1, S)
{
1− I(D = 1)
c(X1, S)
}]
+
√
nE
[{
b̂a(X1, S)− b∗a(X1, S)
}{
1− I(D = 1)
c(X1, S)
}]
.
As E
[
I(D = 1)
c(X1, S)
]
= 1, the first term on the right hand side is equal to zero. Assuming that
√
n(̂ba(X1, S) − b∗a(X1, S)) = OP (1), the second term is also oP (1). These arguments do
not assume that the model b̂a(X1, S) is correctly specified and the required
√
n convergence
(to a potentially misspecified limit) can always be obtained using a parametric model for
b̂a(X1, S).
Next, we rewrite R as
R =
√
nE
[
I(D = 1)
c(X1, S)
ĝa(X) +
I(S = 1, A = a)
p̂(X)ea(X)
{
Y − ĝa(X)
}
− ψ(a)
]
=
√
nE
[{
ĝa(X)− E[Y |X,S = 1, A = a]
}
+
Pr[S = 1, A = a|X]
P̂r[S = 1, A = a|X]
{
E[Y |X,S = 1, A = a]− ĝa(X)
}]
=
√
nE
[{
ĝa(X)− E[Y |X,S = 1, A = a]
}{
1− Pr[S = 1, A = a|X]
P̂r[S = 1, A = a|X]
}]
≤ √nOP (||ĝa(X)− E[Y |X,S = 1, A = a]||2||P̂r[S = 1, A = a|X]− Pr[S = 1, A = a|X]||2),
where the last line follows from the Cauchy-Schwarz inequality and the boundedness of
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P̂r[S = 1, A = a|X] away from zero.
Remark. The term R in Proposition 5 identifies how the estimators of the nuisance pa-
rameters ĝa(X) and P̂ r[S = 1, A = a|X] affect the distribution of ψ̂(a). If the nuisance
parameters converge to the true population parameters at a rate
√
n||ĝa(X)− E[Y |X,S = 1, A = a]||2||Pr[S = 1, A = a|X]− P̂r[S = 1, A = a|X]||2 = oP (1),
the term R in the proposition does not contribute to the asymptotic variance of the estimator.
If the estimators ĝa(X) and p̂(X) come from the class of generalized linear models, the
estimators are Donsker and have a fast enough convergence rate for R to be op(1) if both
models are correct and OP (1) if at least one model is correct (the doubly robustness property
previously discussed). If more data adaptive estimators that do not necessarily converge at
a fast enough rate are used to calculate the nuisance parameters ĝa, and p̂, sample splitting
can be used to control the behavior of R [42].
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Appendix D Asymptotic efficiency
As we have shown previously [1], the estimator in (4), in the absence of sub-sampling, when
the models for ga(X) and p(X) are correctly specified, has asymptotic variance
AVar1 = n
−1
{
E
[
va(X)
p(X)ea(X)
]
+ Var
[
ga(X)
]}
, (D.1)
where va(X) = Var[Y |X,S = 1, A = a]; p(X), ea(X), and ga(X) are as defined above; and
all quantities are evaluated at the true law.
Furthermore, using the influence function result in Appendix B, we obtain, via routine
algebraic manipulation,
E
[{ψ10(a)}2] = E [ va(X)p(X)ea(X)
]
+ Var
[
ga(X)
]
+ E
[
1− c(X1, S)
c(X1, S)
{
ga(X)− ba(X1, S)
}2]
.
Thus, when ga(X) and p(X) are consistently estimated using correctly specified models (and
at sufficiently fast rate), and ba(X1, S) is estimated at
√
n-rate (even with a misspecified
model), the estimator in (3) has asymptotic variance
AVar2 = AVar1 + n
−1 E
[
1− c(X1, S)
c(X1, S)
{
ga(X)− ba(X1, S)
}2]
. (D.2)
Comparing (D.1) and (D.2), we see that
AVar2 ≥ AVar1.
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Appendix E Additional information about the simula-
tion study
Table E.1: Scenarios considered in the simulation study, for covariate dependent sampling
probabilities and continuous X1. For each cohort sample size (n) and average trial sample
size, we provide the γ0 values that result in the desired marginal probability of trial partici-
pation, Pr[S = 1], and the ζ0 values that result in the desired marginal sampling probabilities
among non-randomized individuals, Pr[D = 1|X1, S = 0].
Average
trial size
n Pr[S = 1] γ0
ζ0 values for marginal sampling probabilities
ranging from 0.1 to 0.9, in steps of 0.1
1000
2000 0.5 0
-2.1953125, -1.2929688, -0.6761070,
-0.1483765, 0.3237305, 0.8099365,
1.3345490, 1.9550781, 2.8554688
5000 0.2 -2.055969
-2.3974609, -1.4904175, -0.8675537,
-0.3417969, 0.1408870, 0.6245117,
1.1464232, 1.7731247, 2.6875000
10,000 0.1 -3.154297
-2.47167969, -1.56103516, -0.93359375,
-0.40990990, 0.07421875, 0.56357574,
1.08593750, 1.71679688, 2.62744141
2000
5000 0.4 -0.612793
-2.2607422, -1.3611903, -0.7357330,
-0.2153320, 0.2639160, 0.7441406,
1.2669601, 1.8906250, 2.7956066
10,000 0.2 -2.055969
-2.3974609, -1.4904175, -0.8675537,
-0.3417969, 0.1408870, 0.6245117,
1.1464232, 1.7731247, 2.6875000
20,000 0.1 -3.154297
-2.47167969, -1.56103516, -0.93359375,
-0.40990990, 0.07421875, 0.56357574,
1.08593750, 1.71679688, 2.62744141
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Table E.2: Scenarios considered in the simulation study, for covariate dependent sampling
probabilities and binary X1. For each cohort sample size (n) and average trial sample size,
we provide the γ0 values that result in the desired marginal probability of trial participation,
Pr[S = 1], and the ζ0 values that result in the desired marginal sampling probabilities among
non-randomized individuals, Pr[D = 1|X1, S = 0].
Average
trial size
n Pr[S = 1] γ0
ζ0 values for marginal sampling probabilities
ranging from 0.1 to 0.9, in steps of 0.1
1000
2000 0.5 -0.4973936
-2.70117188, -1.87109375, -1.30666184,
-0.83532715, -0.40234375, 0.02183144,
0.48690367, 1.04687500, 1.88330555
5000 0.2 -2.4145508
-2.7578125, -1.9258423, -1.3582602,
-0.8906250, -0.4609375, -0.0312500,
0.4363470, 0.9983544, 1.8328857
10,000 0.1 -3.460083
-2.77343750, -1.93980408, -1.37890625,
-0.91027832, -0.48046875, -0.05080032,
0.41790675, 0.98059082, 1.81640625
2000
5000 0.4 -1.072715
-2.7205811, -1.8925781, -1.3217773,
-0.8562012, -0.4282227, 0.0078125,
0.4677734, 1.0312500, 1.8676951
10,000 0.2 -2.4145508
-2.7578125, -1.9258423, -1.3582602,
-0.8906250, -0.4609375 -0.0312500,
0.4363470, 0.9983544, 1.8328857
20,000 0.1 -3.460083
-2.77343750, -1.93980408, -1.37890625,
-0.91027832, -0.48046875, -0.05080032,
0.41790675, 0.98059082, 1.81640625
Note: simple random sampling of non-randomized individuals, numerical methods are not
needed to solve for ζ0 and the numerical solutions for γ0 are the same as in the above two
tables.
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Figure E.1: Simulation results for the sampling variance of estimators for ψ(a), a = 0, 1
and ψ(1) − ψ(0), with average trial sample size of 2000 individuals. Results in each panel
are shown for different data generating mechanisms (continuous or binary Z1) and sampling
mechanisms (dependent on Z1 or simple random sampling, SRS). In all panels, results are
shown for ψ̂(a) under marginal sampling probabilities ranging from 0.1 to 0.9, in steps of
0.1 (black markers); and for ψ̂nosub(a) under no sub-sampling (white markers). In each panel,
results are shown for cohort sample sizes of 5000 (circles), 10,000 (triangles), and 20,000
(squares) individuals.
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Figure E.2: CASS analysis results comparing the estimated standard errors of the estimator
in (3) for ψ(a), a = 0, 1 and ψ(1)− ψ(0), under simple random sampling of non-randomized
individuals, against the estimator in (4); see main text for details. In all panels, standard
error ratios are shown for marginal sampling probabilities ranging from 0.1 to 1, in steps of
0.1.
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